Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Immunol Rev. 2011 Jan;239(1):45–61. doi: 10.1111/j.1600-065X.2010.00967.x

Table 1.

Lentiviral vectors as tumor vaccines by ex vivo transduction of antigen-presenting cells or direct in vivo injection

Tumor antigen Vector type Vaccine details Immunity Tumor suppression Ref.
Hepatoma mTAAs (Sca-2, GP38, RABP1) HIV-1 SIN LV/2 VSV-G Twice S.C. injection of LV-transduced BMDCs in BALB/c weekly CTL, secreting IFN-γ Yes (163)
Prostate cancer murine erbB2tr HIV-1 SIN LV /2 VSV-G Twice I.P. injection of LV-transduced BMDCs in C57BL/6 at 2 week interval erbB2tr-specific Th1 cytokine and antibody Yes (164)
Melanoma human MAGE-A3 HIV-1 SIN LV /2 VSV-G Human MoDCs transduced by LV CTL (new epitope EGDCAPEEK) (49, 60, 165)
Melanoma murine TRP2 HIV-1 LV/1 VSV-G S.C. injection of LV-transduced BMDCs in C57BL/6 T-cell response Yes (51, 166)
Melanoma murine TRP2 HIV-1 SIN LV/3 VSV-G Twice I.V. injections of LV in C57BL/6, 1 week apart Ag-specific CD8+ T cells, secreting IFN-γ Yes (68)
Melanoma mTRP2 Breast tumor NeuED HIV-1 SIN LV /2 VSV-G S.C. injection of LV in C57BL/6 or BALB/c-Neu Ag-specific CD8+ T cells, secreting IFN-γ Yes (63)
Melanoma human Melan-A HIV-1 SIN LV/2 VSV-G Human MoDCs transduced by LV Antigen specific CD8+ T cells, secreting IFN-γ N/A (167)
Melanoma hMART1, mTRP2 HIV-1 SIN LV/3 VSV-G S.C. injection of BM cells cotransduced by LV- GM-CSF/IL-4 + LV-hMART 1/mTRP2 in C57BL/6 Antigen specific CD8+ T cells; CTL, secreting IFN-γ Yes (61)
Melanoma human tyrosinase HIV-1 SIN LV/2 VSV-G Human APCs transduced by LV Activation of Ag-specific TILs N/A (44)
Melanoma polyepitope HIV-1 LV/1 VSV-G S.C., I.V., or I.P. injection of LV in HHD mice vigorous and multi-specific long term CTLs N/A (47)
Melanoma human NY-ESO-1 HIV-1 SIN LV/3 VSV-G S.C. injection of LV in HLA-A2/H-2Kb mice Ag-specific T and B-cell responses N/A (162)
Melanoma human NY-ESO-1 HIV-1 SIN LV/2 VSV-G S.C. or I.V. injection of LV in HHD mice; or boost with VV-ESO Ag-specific CD4+ and CD8+ T cells; CTLs N/A (64, 69)
Melanoma human Melan-A/ELA26–35 HIV-1 SIN LV/3 VSV-G S.C. injection of LV in HLA-A2/H-2Kb mice; or boost with the same LV Ag-specific CD8+ T cells N/A (85, 168)
Melanoma human Melan-A26-35 HIV-1 SIN LV/3 VSV-G S.C. injection of LV in HLA-A2/H-2Kb mice; or IL-7 as adjuvant Ag-specific CD8+ memory T cells; CTLs N/A (81, 93)
Melanoma murine mutated TRP1 HIV-1 SIN LV/3 VSV-G Footpad injection of LV in C57BL/6 CD8+ T cells recognizing multi-epitopes; CTL cytokines; TILs Yes (155)
Human telomerase reverse transcriptase HIV-1 SIN LV/2 VSV-G S.C. injection of LV in HHD mice; or boost with peptide/IFA potent and diversified CTLs, secreting IFN-γ Yes (86)